商业保险拒70%品牌药处方

PhRMA· @PhRMA · X·2026-10-01 05:15· 23 小时前AI 评分18

AI 导读

患者为医疗保险支付更多，却得到更少。保险公司和PBM日益控制药品可及性，而患者面临延迟、拒赔和更高的费用。一项近期研究发现，70%的品牌药处方最初被商业保险公司拒绝。是时候让保险发挥其应有的作用了。阅读更多：https://ow.ly/ZgyJ50ZTiH2

正文

Patients are paying more for health insurance and getting less.

Insurers and PBMs increasingly control access to medicines, while patients face delays, denials and higher costs. A recent study found 70% of brand prescriptions are initially denied by commercial insurers.

It's time for insurance to work like it's supposed to.